Compare
SI-BONE, Inc. vs Treace Medical Concepts, Inc. vs Heartflow, Inc. vs Cerus Corp
| Latest fiscal year | SI-BONE, Inc. SIBN | Treace Medical Concepts, Inc. TMCI | Heartflow, Inc. HTFL | Cerus Corp CERS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $200.93M | $212.69M | $176.03M | $233.80M |
| Revenue growth (YoY) | +20.2% | +1.6% | +39.9% | +16.1% |
| Gross margin | 79.6% | 79.8% | 76.8% | n/a |
| Operating margin | -11.1% | -25.5% | -36.4% | -3.7% |
| Net margin | -9.4% | -27.7% | -66.3% | -6.7% |
| Net income | -$18.90M | -$59.00M | -$116.79M | -$15.63M |
| EPS (Diluted) | -$0.44 | -$0.93 | -$3.17 | -$0.08 |
| Operating cash flow | -$675.0K | -$15.97M | -$54.02M | $4.84M |
| Free cash flow | -$9.09M | -$29.49M | -$59.05M | $1.11M |
| Cash & equivalents | $42.24M | $10.71M | $44.78M | $19.96M |
| Total assets | $238.56M | $190.58M | $359.45M | $221.86M |
| Total liabilities | $61.02M | $103.25M | $58.80M | $156.89M |
| Shareholders' equity | $177.53M | $87.33M | $300.65M | $64.22M |
| Return on year-end equity | -10.6% | -67.6% | -38.8% | -24.3% |
| Shares outstanding | 43.65M | n/a | 85.28M | 192.14M |
Revenue, most recent five fiscal years
| Fiscal year | SI-BONE, Inc. | Treace Medical Concepts, Inc. | Heartflow, Inc. | Cerus Corp |
|---|---|---|---|---|
| Latest | $200.93M Ended 2025-12-31 | $212.69M Ended 2025-12-31 | $176.03M Ended 2025-12-31 | $233.80M Ended 2025-12-31 |
| 1 year earlier | $167.18M Ended 2024-12-31 | $209.36M Ended 2024-12-31 | $125.81M Ended 2024-12-31 | $201.32M Ended 2024-12-31 |
| 2 years earlier | $138.89M Ended 2023-12-31 | $187.12M Ended 2023-12-31 | $87.17M Ended 2023-12-31 | $186.80M Ended 2023-12-31 |
| 3 years earlier | $106.41M Ended 2022-12-31 | $141.84M Ended 2022-12-31 | n/a | $188.31M Ended 2022-12-31 |
| 4 years earlier | $90.15M Ended 2021-12-31 | $94.42M Ended 2021-12-31 | n/a | $159.52M Ended 2021-12-31 |